Composition per daily serving
Metabolic improvements (insulin sensitivity, weight stabilization) occur over 3-6 months

Vildagliptin: peripheral oedema and nasopharyngitis Interactions Clinically significant drug interactions are described as follows: *Sitagliptin is metabolised primarily by CYP3A4, in severe renal impairment metabolism plays a more significant role in sitagliptin elimination, therefore potent CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir, clarithromycin) may increase sitagliptin plasma levels in severe renal impairment The blood glucose-lowering effects of DPP-4 inhibitors may also be enhanced or inhibited by other substances: References DPP-4 inhibitors | Prescribing information | Diabetes type 2 | CKS | NICE Sitagliptin 100 mg Film-coated Tablets Summary of Product Characteristics (SmPC) (emc) Onglyza 2.5mg film-coated tablets Summary of Product Characteristics (SmPC) (emc) Trajenta 5 mg film-coated tablets Summary of Product Characteristics (SmPC) (emc) Alogliptin 12.5 mg film-coated tablets Summary of Product Characteristics (SmPC) (emc)

Chetan, you've talked about the near-term super cycle, and I think there's a near-term aggregate demand side to AI, but over the longer term, maybe it's more supply
Specifically, NF-B competes with E2F1 for binding to the Bnip3 promoter, thereby preventing Bnip3-mediated mitochondrial clearance
Meal replacements are essential because they ensure you're getting proper nutrition despite eating less